An update on CAR-T therapies for MM and B-cell NHL presented at the 2026 ONA Summit highlighted the integral role of oncology nurses in ensuring patients achieve optimal outcomes.
Post hoc analyses of pivotal MITIGATE trial show broad efficacy across patient subgroups with differing organ involvement and clinical characteristics.
Outcomes remained poor overall, underscoring the need for clinical trials and novel therapies in this setting.
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results Twenty-eight ...
In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results